Active — Not RecruitingPhase 1

MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer

United States26 participantsStarted 2018-08-03

Plain-language summary

This trial studies how well magnetic resonance imaging (MRI)-guided internal radiation therapy (brachytherapy) works in treating participants with human papillomavirus (HPV) associated stage IB2-IV cervical or stage II-IVA vaginal cancer. Using MRI guidance during brachytherapy applicator placement may improve treatment planning in participants with cervical or vaginal cancer.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women with stage 1B2-IVA cervical cancer recommended to receive definitive chemoradiation including brachytherapy; or * Women with stage II-IVA vaginal cancer recommended to receive definitive chemoradiation including brachytherapy. Exclusion Criteria: * Patient or tumor anatomy that requires use of a non-MRI-compatible applicator. * Patients with implantable cardioverter-defibrillator, pacemaker or other implanted device or medical condition which precludes MRI acquisition.

What they're measuring

Percent of patients achieving high-risk clinical target volume (HR-CTV) dose to 90% (D90)

Timeframe: Up to 4 years

Trial details

NCT IDNCT03634267

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Human Papillomavirus-Related Carcinoma trials